Reviewing CareDx (CDNA) & Its Peers

CareDx (NASDAQ:CDNA – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare CareDx to related businesses based on the strength of its analyst recommendations, earnings, valuation, risk, dividends, profitability and institutional ownership.

Risk and Volatility

CareDx has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500. Comparatively, CareDx’s peers have a beta of -1.85, meaning that their average stock price is 285% less volatile than the S&P 500.

Insider & Institutional Ownership

47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 2.4% of CareDx shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares CareDx and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CareDx 25.86% 9.74% 7.35%
CareDx Competitors -12,519.20% -215.47% -31.42%

Valuation and Earnings

This table compares CareDx and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CareDx $379.80 million -$21.35 million 29.22
CareDx Competitors $713.93 million $9.18 million -17.98

CareDx’s peers have higher revenue and earnings than CareDx. CareDx is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for CareDx and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CareDx 0 4 4 1 2.67
CareDx Competitors 9959 15361 45766 1602 2.54

CareDx presently has a consensus price target of $70.33, suggesting a potential upside of 0.70%. As a group, “Biotechnology” companies have a potential upside of 115.28%. Given CareDx’s peers higher possible upside, analysts clearly believe CareDx has less favorable growth aspects than its peers.

Summary

CareDx beats its peers on 7 of the 13 factors compared.

CareDx Company Profile

(Get Free Report)

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.